Mon - Fri : 09:00 - 15:00
INFO@PACIFICEQUITYUSA.COM
858.886.7237

Investor Spotlight Daily

The #1 Publication for Small Cap & Emerging Micro-Cap Growth companies in North America

2020 Marijuana Sales are Expected to Reach Nearly $23 Billion

//
Posted By
/
Comment0
/
Categories

By 2020 Marijuana Sales are Expected to Reach Nearly $23 Billion With Predictions 2016 Will Be the Greenest Year in History; Company Executes International License Agreement

As illustrated by the Spring 2016 Marijuana Business Conference & Expo earlier this month, the numbers and momentum of cannabis in the US are undeniable. As revenues continue to climb into the billions, more research and development push the sector forward. According to the newly released 4th Edition State of Legal Marijuana Markets Report from from ArcView Market Research and New Frontier, a cannabis-focused data-analysis firm, much of the increase in sector is attributed to adult use market sales, which hit $1.3 billion last year alone. By 2020, adult use and medical marijuana sales are expected to reach nearly $23 billion.
In breaking marijuana products & license advancements in the markets recently: Green Cures & Botanical Distribution Inc. (OTC Pink: GRCU) (“Green Cures”), a cannabis and industrial hemp products innovator, announced today that the company has executed an exclusive U.S. supply agreement of legal industrial hemp-whole plant extraction CBD Oil with JustUs Aquaponics, LLC.
Management of Green Cures stated that with the access to this new source of supply of CBD Oil, the company will be able to offer to the consumer unlimited inventory of its botanical and medicinal cannabis derived formulas labeled Green Cures. Currently, the line of products Green Cures is available for purchase at www.allcbd.com, which is one of the company’s exclusive ecommerce website dedicated to the marketing and sale of CBD derived products in the U.S., as permitted by law. Additionally, the company announced that new and improved formulas with higher CBD potency are expected to be introduced to the consumers in the very near future.
JustUs Aquaponics, LLC is a privately held U.S. company that is also led by Dr. Trent Jones. JustUs Aquaponics, LLC provides Cannabidiol (CBD) oil, which is extracted from whole plant industrial hemp. This form of CBD is especially potent because it delivers the full complement of cannabinoids, terpenes and flavonoids found in the industrial hemp plant. Industrial hemp is defined as the Cannabis sativa plant that contains less than 0.3% Delta-9 THC in the dried plant. The industrial hemp plants cultivated by JustUs Aquaponics, LLC are well below the federal 0.3% Delta-9 THC limit, while delivering considerable levels of Cannabidiol, as well as the critically important terpenes and flavonoid molecules.

Freedom Leaf, Inc. (OTC: FRLF) is proud to announce the international expansion of its print and multimedia platform, as well as its portfolio of products and services in the Netherlands. Freedom Leaf, Inc. has entered into an International License Agreement secured by a $25,000 non-refundable deposit for the exclusive license to use the Freedom Leaf Brand with the right to publish the Freedom Leaf magazine in Dutch offering Advertising, while also undertaking Public Relations, Business Consulting, Branding Services, Business Development and Incubation for the Cannabis companies in the Netherlands. Freedom Leaf, Netherlands will also distribute branded products and services and will identify emerging opportunities to bring under the Freedom Leaf umbrella in the US and the Netherlands.
In other Legal Marijuana / Cannabis / Cannabidol News and Developments in the markets: Insys Therapeutics, Inc. (NASDAQ: INSY) announced that it has successfully completed its Phase 1/Phase 2 safety and pharmacokinetic (PK) study in pediatric subjects with treatment-resistant epilepsy. In this trial, 61 subjects with refractory epilepsy, between the ages of 1 year to 17 years, received treatment with Insys’ pharmaceutical cannabidiol (CBD) oral solution across multiple investigative sites in the United States. The clinical trial evaluated multiple ascending doses of Insys’ CBD with three cohorts of subjects receiving total daily doses of 10 mg/kg, 20 mg/kg or 40 mg/kg. Over 80% of these subjects continue to receive CBD in an ongoing long-term safety study.
84% support medical marijuana – If you thought full legalization support was high, you haven’t seen anything yet. Based on a CBS News poll conducted in April 2015, 84% of those surveyed wanted to see marijuana legalized for medicinal use nationwide. It’s not hard to understand why, either, with companies like GW Pharmaceuticals (NASDAQ: GWPH) showcasing the many uses of cannabinoids in early- and mid-stage clinical trials. For instance, GW Pharmaceuticals’ Epidiolex helped reduced seizure frequency by more than 50% in two midstage studies for childhood-onset epilepsy in Dravet syndrome and Lennox-Gastaut syndrome. Read the full Article at http://www.fool.com/investing/general/2016/05/22/9-fast-facts-about-marijuana-including-1-telling-s.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2
Terra Tech Corp. (OTC: TRTC), recently announced that its subsidiary, Edible Garden, a retail seller of locally grown hydroponic produce, herbs, and floral products, has shipped its first order of nutritionally-enhanced lettuce to ShopRite Supermarkets. The lettuce was developed in partnership with Nutrasorb LLC under the name SUPERLEAF™, in conjunction with Rutgers University, and is the latest addition to Edible Garden’s product line of non-GMO fruits and vegetables.
Medical Marijuana, Inc. (OTC: MJNA) is pleased to announce that its hemp biotech investment, AXIM Biotechnologies, Inc. (AXIM), has begun the world’s first human dermatological clinical trials on psoriasis (PsO) and atopic dermatitis (AD) commonly known as eczema based on AXIM’s AX-1602 proprietary, patent-pending topical ointment formulation containing cannabigerol (CBG) and other cannabinoids. Conducting the clinical trials is a world-renowned dermatologist and specialist on psoriasis and atopic dermatitis, Dr. Marcus Meinardi, at The Maurits Clinics in The Hague, The Netherlands. Psoriasis and eczema are estimated to affect nearly 200 million people worldwide by 2024 with combined market estimates at $16 billion by 2022.

Investor Spotlight Daily Research coverage specializes in online financial publication of small and micro-cap companies that are under-followed or under-valued by Wall Street. Our analyst seeks to identify and report on these companies, bringing to investors a unique opportunity to gain insight on small-cap investments which are believed to be under-valued and well-positioned for future growth. Our goal is to produce high quality (institutional) research for the small cap portfolio.
DISCLAIMER

Investor Spotlight Daily is an analytical research firm hired by companies and third parties to provide Investor Awareness services. This disclaimer is to be read and understood before using Information. Investor Spotlight Daily distributes research and other Information purchased and compiled from outside sources and analysts. This report/release/advertisement is hereinafter defined as a commercial advertisement and is for general Information purposes only. Do not base any investment decision or rely on Information in this commercial advertisement including financial projections, price targets which are academic theory, buy/sell and trading recommendations and forecasted business prospects. Never invest in any stock or commercial advertisement featured, distributed, posted, written and/or edited by Investor Spotlight Daily or a third party on web sites, emails, newsletters, or other media unless you can afford to lose your entire investment. All Information should be validated by the issuing company. This publication is not provided to any particular individual with a view toward their investment circumstances. Investor Spotlight Daily does not give investment advice and is not a registered Investment Advisor or a member of any association for other research providers. Under no circumstances is this commercial advertisement to be used or considered as an offer to sell or a solicitation of any offer to buy any security or other debt instruments, or any options, futures or other derivatives related to such securities herein. By accessing, viewing or using our website, commercial advertisements or communications, you agree that you alone bear complete responsibility for your own investment research, due diligence and investment decisions. The majority of these profiled companies are highly risky OTC Bulletin Board or Pink Sheet companies.

Release of Liability

Investor Spotlight Daily assumes no liability for any short term or long term investment decision by any investor of our recommended stocks or any third party’s use of Investor Spotlight Daily research materials. The reader of the Information hereby indemnifies Investor Spotlight Daily from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to the disseminated Information. The reader acknowledges that Investor Spotlight Daily will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of Information in this commercial advertisement, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of Information, products or services from any person or entity including but not limited to lost profits, loss of opportunities, trading losses, and damages that may result from any incompleteness or inaccuracy in any of Investor Spotlight Daily’s profiled companies or third party research of the disseminated Information. Investor Spotlight Daily does not undertake any responsibility whatsoever for updating the Information contained in its prior publications.

.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and GRCU undertakes no obligation to update such statements.

Contact Information:
Company: Invesor Spotlight Daily
Contact email: INFO@INVESTORSPOTLIGHTDAILY
U.S. Phone: (858) 886-7238
URL: www.investorspotlightdaily.com
Source: Investor Spotlight Daily

Leave a Reply